Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

Korábbi kezelés

• Subjects who are currently taking amyloid reducing therapy.
• Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).
• Active treatment with one or more anti-epileptic agent.
• Subjects who have had eye surgery in the last 3 months or are scheduled to have eye surgery in the next 6 months (during the study)
• Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.

Más betegség

• Subjects who meet any of the following conditions will not be enrolled in the study:
• Active treatment on a dosage of one or more psychiatric agents (e.g. antidepressants, antipsychotics, etc) for LESS THAN three months (a stable dose for greater than or equal to three months is ok).
• Subjects who are actively diagnosed with cancer and undergoing cancer-related treatments
• Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.
• Subjects with history of seizure or epilepsy
• Subjects who have had a stroke within the past 24 months.
• Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and/or sacral nerve stimulator.
• Subjects who have profound hearing or visual impairment.

Egyéb

• Subjects who do not have healthcare.
• Subjects who have > 4 cerebral microbleeds or 1 macrobleed in their brain
• Subjects with clinically significant suicide risk and/or suicide attempt in the past 1 year.
• Subjects with behavioral problems such as aggression/agitation/impulsivity that might interfere with their ability to comply with protocol.
• Subjects with untreated or unstable depression
• Subjects diagnosed with migraine headache.
• Subjects who have a life expectancy of less than 2 years.
• Subjects who are pregnant.

• Subjects may be enrolled into the study if they meet all of the following criteria:
• Subject is between the ages of 65 - 100.
• Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19-26.
• Subject is willing to sign informed consent document.
• If subject is deemed to not have capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent.
• Able to complete the 1st month of at home stimulation at their primary residence. If subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.